Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.
Sean WhartonMelanie Jane DaviesDror DickerIldiko LingvayLawrence A LeiterDomenica M RubinoSue D PedersenPublished in: Postgraduate medicine (2021)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.
Keyphrases
- clinical practice
- weight loss
- type diabetes
- weight gain
- insulin resistance
- glycemic control
- metabolic syndrome
- body mass index
- high fat diet induced
- physical activity
- wild type
- primary care
- cardiovascular disease
- randomized controlled trial
- systematic review
- drug administration
- risk assessment
- human health
- body weight